Recent advances in antithrombotic treatment for acute coronary syndromes

Expert Rev Clin Pharmacol. 2014 Jul;7(4):507-21. doi: 10.1586/17512433.2014.923306. Epub 2014 May 31.

Abstract

Anti-thrombotic drugs constitute the cornerstone of therapy in the management of acute coronary syndromes (ACS) and for patients undergoing percutaneous coronary intervention. Anti-thrombotic therapy during percutaneous coronary intervention for ACS has evolved substantially over the past 15 years. In the original 1996 ACC/AHA guidelines for the management of acute myocardial infarction (MI), only one antiplatelet agent (aspirin) and one anticoagulant (unfractionated heparin) were recommended as class I therapies. Much has since changed and the contemporary therapeutic armoury for the treatment of ACS reflects the pharmacological advances that have taken place. Recent developments in the medical management of ACS have been based around developing drugs with more predictable efficacy and at known drug targets. However there has also been considerable development of novel agents. New pharmacotherapies for ACS reflect efforts to improve efficacy and minimize complications by increasing target specificity and reducing inter-individual variation in therapeutic response.

Keywords: NSTEMI; PCI; STEMI; acute coronary syndrome; anticoagulant; antiplatelet; antithrombotic; myocardial infarction.

Publication types

  • Review

MeSH terms

  • Acute Coronary Syndrome / drug therapy*
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Randomized Controlled Trials as Topic

Substances

  • Fibrinolytic Agents